{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:23:24Z","timestamp":1789025004165,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2012R1A4A1028835"],"award-info":[{"award-number":["2012R1A4A1028835"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1A5A2017323"],"award-info":[{"award-number":["2020R1A5A2017323"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2017R1A2B3002227"],"award-info":[{"award-number":["2017R1A2B3002227"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Conventional therapeutic approaches for tumor angiogenesis, which are primarily focused on the inhibition of active angiogenesis to starve cancerous cells, target the vascular endothelial growth factor signaling pathway. This aggravates hypoxia within the tumor core and ultimately leads to increased tumor proliferation and metastasis. To overcome this limitation, we developed nanoparticles with antiseptic activity that target tumor vascular abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ferritin-based protein C nanoparticles (PCNs), known as TFG and TFMG, were generated and tested in Lewis lung carcinoma (LLC) allograft and MMTV-PyMT spontaneous breast cancer models. Immunohistochemical analysis was performed on tumor samples to evaluate the tumor vasculature. Western blot and permeability assays were used to explore the role and mechanism of the antitumor effects of PCNs in vivo. For knocking down proteins of interest, endothelial cells were transfected with siRNAs. Statistical analysis was performed using one-way ANOVA followed by post hoc Dunnett\u2019s multiple comparison test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PCNs significantly inhibited hypoxia and increased pericyte coverage, leading to the inhibition of tumor growth and metastasis, while increasing survival in LLC allograft and MMTV-PyMT spontaneous breast cancer models. The coadministration of cisplatin with PCNs induced a synergistic suppression of tumor growth by improving drug delivery as evidenced by increased blood prefusion and decreased vascular permeability. Moreover, PCNs altered the immune cell profiles within the tumor by increasing cytotoxic T cells and M1-like macrophages with antitumor activity. PCNs induced PAR-1\/PAR-3 heterodimerization through EPCR occupation and PAR-1 activation, which resulted in G\u03b113-RhoA-mediated-Tie2 activation and stabilized vascular tight junctions via the Akt-FoxO3a signaling pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cancer treatment targeting the tumor vasculature by inducing antitumor immune responses and enhancing the delivery of a chemotherapeutic agent with PCNs resulted in tumor regression and may provide an effective therapeutic strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-020-00952-9","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T06:02:59Z","timestamp":1600063379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Tie2-mediated vascular remodeling by ferritin-based protein C nanoparticles confers antitumor and anti-metastatic activities"],"prefix":"10.1186","volume":"13","author":[{"given":"Young Sun","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeonha","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biki","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hak","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Soon","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Oh","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Sup","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Im-Sook","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-San","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5756-7169","authenticated-orcid":false,"given":"You Mie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"issue":"7347","key":"952_CR1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Natur. 2011;473(7347):298\u2013307 Epub 2011\/05\/20.","journal-title":"Natur"},{"issue":"5","key":"952_CR2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605\u201322 Epub 2014\/12\/18.","journal-title":"Cancer Cell"},{"issue":"5","key":"952_CR3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cell.2009.01.020","volume":"136","author":"M Mazzone","year":"2009","unstructured":"Mazzone M, Dettori D, de Oliveira RL, Loges S, Schmidt T, Jonckx B, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009;136(5):839\u201351 Epub 2009\/02\/17.","journal-title":"Cell"},{"issue":"1","key":"952_CR4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ccr.2013.12.010","volume":"25","author":"C Kim","year":"2014","unstructured":"Kim C, Yang H, Fukushima Y, Saw PE, Lee J, Park JS, et al. Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption. Cancer Cell. 2014;25(1):102\u201317 Epub 2014\/01\/18.","journal-title":"Cancer Cell"},{"issue":"7070","key":"952_CR5","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967\u201374.","journal-title":"Nature."},{"issue":"114","key":"952_CR6","first-page":"114rv3","volume":"3","author":"Y Cao","year":"2011","unstructured":"Cao Y, Arbiser J, D'Amato RJ, D'Amore PA, Ingber DE, Kerbel R, et al. Forty-year journey of angiogenesis translational research. Sci Transl Med. 2011;3(114):114rv3 Epub 2011\/12\/23.","journal-title":"Sci Transl Med"},{"issue":"4","key":"952_CR7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","volume":"8","author":"O Casanovas","year":"2005","unstructured":"Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8(4):299\u2013309 Epub 2005\/10\/18.","journal-title":"Cancer Cell"},{"issue":"4","key":"952_CR8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nrclinonc.2011.21","volume":"8","author":"JM Ebos","year":"2011","unstructured":"Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8(4):210\u201321 Epub 2011\/03\/03.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"952_CR9","doi-asserted-by":"crossref","first-page":"a006486","DOI":"10.1101\/cshperspect.a006486","volume":"2","author":"S Goel","year":"2012","unstructured":"Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012;2(3):a006486 Epub 2012\/03\/07.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6453","key":"952_CR10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/science.aaw7875","volume":"365","author":"LL Munn","year":"2019","unstructured":"Munn LL, Jain RK. Vascular regulation of antitumor immunity. Science. 2019;365(6453):544\u20135 Epub 2019\/08\/10.","journal-title":"Science"},{"issue":"42","key":"952_CR11","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.1002\/adma.201503093","volume":"27","author":"W Lee","year":"2015","unstructured":"Lee W, Seo J, Kwak S, Park EJ, Na DH, Kim S, et al. A Double-chambered protein nanocage loaded with thrombin receptor agonist peptide (TRAP) and gamma-Carboxyglutamic acid of protein C (PC-Gla) for sepsis treatment. Adv Mater. 2015;27(42):6637\u201343 Epub 2015\/09\/29.","journal-title":"Adv Mater"},{"issue":"8","key":"952_CR12","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2006-09-003004","volume":"109","author":"LO Mosnier","year":"2007","unstructured":"Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109(8):3161\u201372 Epub 2006\/11\/18.","journal-title":"Blood"},{"issue":"6","key":"952_CR13","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2009-09-201616","volume":"115","author":"S Danese","year":"2010","unstructured":"Danese S, Vetrano S, Zhang L, Poplis VA, Castellino FJ. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood. 2010;115(6):1121\u201330 Epub 2009\/12\/19.","journal-title":"Blood"},{"issue":"19","key":"952_CR14","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1182\/blood-2015-02-355974","volume":"125","author":"JH Griffin","year":"2015","unstructured":"Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood. 2015;125(19):2898\u2013907 Epub 2015\/04\/01.","journal-title":"Blood"},{"issue":"8","key":"952_CR15","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1182\/blood-2004-10-3985","volume":"105","author":"C Feistritzer","year":"2005","unstructured":"Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005;105(8):3178\u201384 Epub 2005\/01\/01.","journal-title":"Blood"},{"issue":"12","key":"952_CR16","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2007-06-096651","volume":"110","author":"JS Bae","year":"2007","unstructured":"Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood. 2007;110(12):3909\u201316 Epub 2007\/09\/08.","journal-title":"Blood"},{"issue":"3","key":"952_CR17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1039\/C7NR08188J","volume":"10","author":"Z Wang","year":"2018","unstructured":"Wang Z, Dai Y, Wang Z, Jacobson O, Zhang F, Yung BC, et al. Metal ion assisted interface re-engineering of a ferritin nanocage for enhanced biofunctions and cancer therapy. Nanoscale. 2018;10(3):1135\u201344 Epub 2017\/12\/23.","journal-title":"Nanoscale"},{"issue":"4","key":"952_CR18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11705-017-1620-8","volume":"11","author":"Z Wang","year":"2017","unstructured":"Wang Z, Gao H, Zhang Y, Liu G, Niu G, Chen X. Functional ferritin nanoparticles for biomedical applications. Front Chem Sci Eng. 2017;11(4):633\u201346 Epub 2018\/03\/06.","journal-title":"Front Chem Sci Eng"},{"key":"952_CR19","first-page":"928315","volume":"2013","author":"Q Chen","year":"2013","unstructured":"Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm. 2013;2013:928315 Epub 2013\/07\/11.","journal-title":"Mediators Inflamm"},{"issue":"Pt 4","key":"952_CR20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1242\/jcs.140103","volume":"127","author":"BM Gumbiner","year":"2014","unstructured":"Gumbiner BM, Kim NG. The Hippo-YAP signaling pathway and contact inhibition of growth. J Cell Sci. 2014;127(Pt 4):709\u201317 Epub 2014\/02\/18.","journal-title":"J Cell Sci"},{"issue":"6","key":"952_CR21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ccell.2016.10.018","volume":"30","author":"JS Park","year":"2016","unstructured":"Park JS, Kim IK, Han S, Park I, Kim C, Bae J, et al. Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell. 2016;30(6):953\u201367 Epub 2016\/12\/14.","journal-title":"Cancer Cell"},{"issue":"9","key":"952_CR22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nchembio817","volume":"2","author":"JB Fitzgerald","year":"2006","unstructured":"Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol. 2006;2(9):458\u201366 Epub 2006\/08\/22.","journal-title":"Nat Chem Biol"},{"issue":"7","key":"952_CR23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/00986440701215531","volume":"194","author":"D Gonzalez","year":"2007","unstructured":"Gonzalez D, Nasibulin AG, Jiang H, Queipo P, Kauppinen EI. Electrospraying of ferritin solutions for the production of monodisperse iron oxide nanoparticles. Chem Eng Commun. 2007;194(7):901\u201312.","journal-title":"Chem Eng Commun"},{"issue":"10","key":"952_CR24","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","volume":"73","author":"Y Huang","year":"2013","unstructured":"Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73(10):2943\u20138 Epub 2013\/02\/27.","journal-title":"Cancer Res"},{"issue":"1","key":"952_CR25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ccr.2010.11.009","volume":"19","author":"C Rolny","year":"2011","unstructured":"Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011;19(1):31\u201344 Epub 2011\/01\/11.","journal-title":"Cancer Cell"},{"issue":"43","key":"952_CR26","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109(43):17561\u20136 Epub 2012\/10\/10.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"952_CR27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gde.2007.12.007","volume":"18","author":"S Ostrand-Rosenberg","year":"2008","unstructured":"Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev. 2008;18(1):11\u20138 Epub 2008\/03\/01.","journal-title":"Curr Opin Genet Dev"},{"issue":"12","key":"952_CR28","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","volume":"164","author":"CD Mills","year":"2000","unstructured":"Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1\/M-2 macrophages and the Th1\/Th2 paradigm. J Immunol. 2000;164(12):6166\u201373 Epub 2000\/06\/08.","journal-title":"J Immunol"},{"key":"952_CR29","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.addr.2017.04.010","volume":"114","author":"C Ngambenjawong","year":"2017","unstructured":"Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017;114:206\u201321 Epub 2017\/04\/30.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"952_CR30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","volume":"122","author":"A Sica","year":"2012","unstructured":"Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787\u201395 Epub 2012\/03\/02.","journal-title":"J Clin Invest"},{"issue":"7","key":"952_CR31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416 Epub 2017\/01\/25.","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"952_CR32","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1073\/pnas.0700763104","volume":"104","author":"JN McLaughlin","year":"2007","unstructured":"McLaughlin JN, Patterson MM, Malik AB. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proce Natl Acad Sci U S A. 2007;104(13):5662\u20137 Epub 2007\/03\/23.","journal-title":"Proce Natl Acad Sci U S A"},{"issue":"16","key":"952_CR33","doi-asserted-by":"crossref","first-page":"11203","DOI":"10.1074\/jbc.M112.439950","volume":"288","author":"H Lin","year":"2013","unstructured":"Lin H, Trejo J. Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits beta-arrestin-mediated endosomal signaling. J Biol Chem. 2013;288(16):11203\u201315 Epub 2013\/03\/12.","journal-title":"J Biol Chem"},{"issue":"45","key":"952_CR34","doi-asserted-by":"crossref","first-page":"32553","DOI":"10.1074\/jbc.M113.472373","volume":"288","author":"A Arachiche","year":"2013","unstructured":"Arachiche A, Mumaw MM, de la Fuente M, Nieman MT. Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by alpha-thrombin. J Biol Chem. 2013;288(45):32553\u201362 Epub 2013\/10\/08.","journal-title":"J Biol Chem"},{"issue":"2","key":"952_CR35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1182\/blood-2015-11-636472","volume":"128","author":"MT Nieman","year":"2016","unstructured":"Nieman MT. Protease-activated receptors in hemostasis. Blood. 2016;128(2):169\u201377 Epub 2016\/04\/30.","journal-title":"Blood"},{"issue":"Suppl 2","key":"952_CR36","doi-asserted-by":"crossref","first-page":"S317","DOI":"10.21037\/tcr.2017.03.64","volume":"6","author":"J Fueyo","year":"2017","unstructured":"Fueyo J, Hossain MB, Nguyen T, Gomez-Manzano C. Normalizing tumoral vessels to treat cancer: an out-of-the-box strategy involving TIE2 Pathway. Transl Cancer Res. 2017;6(Suppl 2):S317\u2013s20 Epub 2017\/09\/26.","journal-title":"Transl Cancer Res"},{"issue":"23","key":"952_CR37","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1182\/blood-2014-06-582775","volume":"124","author":"F Stavenuiter","year":"2014","unstructured":"Stavenuiter F, Mosnier LO. Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity. Blood. 2014;124(23):3480\u20139 Epub 2014\/10\/17.","journal-title":"Blood"},{"key":"952_CR38","doi-asserted-by":"crossref","first-page":"16106","DOI":"10.1038\/ncomms16106","volume":"8","author":"M Teichert","year":"2017","unstructured":"Teichert M, Milde L, Holm A, Stanicek L, Gengenbacher N, Savant S, et al. Pericyte-expressed Tie2 controls angiogenesis and vessel maturation. Nat Commun. 2017;8:16106 Epub 2017\/07\/19.","journal-title":"Nat Commun"},{"key":"952_CR39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neulet.2015.05.028","volume":"599","author":"T Machida","year":"2015","unstructured":"Machida T, Takata F, Matsumoto J, Takenoshita H, Kimura I, Yamauchi A, et al. Brain pericytes are the most thrombin-sensitive matrix metalloproteinase-9-releasing cell type constituting the blood-brain barrier in vitro. Neurosci Lett. 2015;599:109\u201314 Epub 2015\/05\/24.","journal-title":"Neurosci Lett"},{"issue":"6","key":"952_CR40","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0002-9440(10)64675-5","volume":"158","author":"MR D'Andrea","year":"2001","unstructured":"D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol. 2001;158(6):2031\u201341 Epub 2001\/06\/08.","journal-title":"Am J Pathol"},{"issue":"4","key":"952_CR41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1601-0825.2006.01317.x","volume":"13","author":"S Ketabchi","year":"2007","unstructured":"Ketabchi S, Massi D, Ficarra G, Rubino I, Franchi A, Paglierani M, et al. Expression of protease-activated receptor-1 and -2 in orofacial granulomatosis. Oral Dis. 2007;13(4):419\u201325 Epub 2007\/06\/20.","journal-title":"Oral Dis"},{"issue":"2","key":"952_CR42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd.2017.4","volume":"16","author":"M Cully","year":"2017","unstructured":"Cully M. Cancer: Tumour vessel normalization takes centre stage. Nat Rev Drug Discov. 2017;16(2):87 Epub 2017\/02\/06.","journal-title":"Nat Rev Drug Discov"},{"issue":"21","key":"952_CR43","doi-asserted-by":"crossref","first-page":"R1161","DOI":"10.1016\/j.cub.2016.09.043","volume":"26","author":"PP Wong","year":"2016","unstructured":"Wong PP, Bodrug N, Hodivala-Dilke KM. Exploring novel methods for modulating tumor blood vessels in cancer treatment. Curr Biol. 2016;26(21):R1161\u2013r6 Epub 2016\/11\/09.","journal-title":"Curr Biol"},{"issue":"4","key":"952_CR44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s004180100328","volume":"116","author":"PL Debbage","year":"2001","unstructured":"Debbage PL, Solder E, Seidl S, Hutzler P, Hugl B, Ofner D, et al. Intravital lectin perfusion analysis of vascular permeability in human micro- and macro- blood vessels. Histochem Cell Biol. 2001;116(4):349\u201359 Epub 2001\/11\/10.","journal-title":"Histochem Cell Biol"},{"key":"952_CR45","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/srep01932","volume":"3","author":"G Egawa","year":"2013","unstructured":"Egawa G, Nakamizo S, Natsuaki Y, Doi H, Miyachi Y, Kabashima K. Intravital analysis of vascular permeability in mice using two-photon microscopy. Scientific reports. 2013;3:1932 Epub 2013\/06\/05.","journal-title":"Scientific reports."},{"issue":"8","key":"952_CR46","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1111\/j.1538-7836.2012.04825.x","volume":"10","author":"RA Schuepbach","year":"2012","unstructured":"Schuepbach RA, Madon J, Ender M, Galli P, Riewald M. Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects. J Thromb Haemost. 2012;10(8):1675\u201384 Epub 2012\/06\/21.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"952_CR47","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ccell.2016.10.018","volume":"30","author":"J-S Park","year":"2016","unstructured":"Park J-S, Kim I-K, Han S, Park I, Kim C, Bae J, et al. Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell. 2016;30(6):953\u201367.","journal-title":"Cancer Cell"},{"issue":"1","key":"952_CR48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1476-5381.2009.00121.x","volume":"158","author":"S Siehler","year":"2009","unstructured":"Siehler S. Regulation of RhoGEF proteins by G12\/13-coupled receptors. Br J Pharmacol. 2009;158(1):41\u20139 Epub 2009\/02\/20.","journal-title":"Br J Pharmacol"},{"issue":"20","key":"952_CR49","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1007\/s00018-016-2232-z","volume":"73","author":"F Gao","year":"2016","unstructured":"Gao F, Artham S, Sabbineni H, Al-Azayzih A, Peng XD, Hay N, et al. Akt1 promotes stimuli-induced endothelial-barrier protection through FoxO-mediated tight-junction protein turnover. Cell Mol Life Sci. 2016;73(20):3917\u201333 Epub 2016\/04\/27.","journal-title":"Cell Mol Life Sci"},{"key":"952_CR50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","volume":"108","author":"JI Hare","year":"2017","unstructured":"Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv Drug Deliv Rev. 2017;108:25\u201338 Epub 2016\/05\/04.","journal-title":"Adv Drug Deliv Rev"},{"issue":"29","key":"952_CR51","doi-asserted-by":"crossref","first-page":"24392","DOI":"10.1021\/acsami.8b06642","volume":"10","author":"B Gupta","year":"2018","unstructured":"Gupta B, Ruttala HB, Poudel BK, Pathak S, Regmi S, Gautam M, et al. Polyamino acid layer-by-layer (LbL) constructed silica-supported mesoporous titania nanocarriers for stimuli-responsive delivery of microRNA 708 and paclitaxel for combined chemotherapy. ACS Appl Mater Interfaces. 2018;10(29):24392\u2013405 Epub 2018\/07\/07.","journal-title":"ACS Appl Mater Interfaces"},{"key":"952_CR52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fonc.2013.00211","volume":"3","author":"S Azzi","year":"2013","unstructured":"Azzi S, Hebda JK, Gavard J. Vascular permeability and drug delivery in cancers. Front Oncol. 2013;3:211 Epub 2013\/08\/24.","journal-title":"Front Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00952-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-00952-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00952-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T20:08:27Z","timestamp":1631563707000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00952-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00952-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"23 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}